Detecting Inherited Cholesterol Before It Strikes
2026-09-01
Invisible cholesterol damage, not dramatic heart attacks, is what cardiologists say should dominate public health planning. Familial hypercholesterolemia, an inherited disorder that drives low‑density lipoprotein far above normal from birth, quietly injures arterial walls long before symptoms appear, through endothelial dysfunction and accelerated atherosclerotic plaque formation.
The real scandal, experts argue, is not the mutation itself but the missed chances to find it. Clinical guidelines describe familial hypercholesterolemia with clear diagnostic criteria, yet many primary care systems still rely on opportunistic checks instead of structured cascade screening across families. That delay means people often start statin therapy, PCSK9 inhibition or lipoprotein apheresis only after advanced coronary artery disease is established.
Preventive cardiology teams now push for a simple shift: treat extreme low‑density lipoprotein levels in children and young adults as a red flag, not a curiosity. Routine lipid panels in childhood, automatic referral when thresholds are exceeded, and wider access to DNA sequencing for known pathogenic variants are being promoted as low‑tech, high‑yield steps. Health services that embed this strategy, specialists contend, will trade a small rise in early testing costs for a large fall in intensive care admissions.
Loading...
